- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
BREA, Calif., US: Envista Holdings, the company behind leading dental brands such as Nobel Biocare, Ormco, DEXIS and Kerr, has begun the process of finding a successor for CEO Amir Aghdaei. Envista’s board of directors has formed a search committee and retained an executive search firm to find qualified external candidates to lead the next phase of operations for the dental giant, and the succession process is expected to be completed this year.
Aghdaei commented: “After nearly ten years leading Danaher’s dental platform and the Envista team, it is now time to focus on the next phase of building a world-class dental company. Finding a strong successor will ensure that we continue our journey to digitise, personalise, and democratise the dental industry. After the appointment of a new leader, I will provide support to ensure a smooth transition, as needed.”
He added: “As we go through this process, I remain focused on driving our near-term transformation while ensuring we are positioned to achieve our long-term priorities of accelerating growth, expanding margins and transforming the portfolio. I am incredibly proud of the Envista team and am committed to our long-term success.”
Chairman of the Board Scott Huennekens said: “Amir has led the company during a pivotal time, including through the spin-off from Danaher and the challenges of the global pandemic. We are grateful for the many contributions he has made over the past ten years. He was instrumental in the founding of Envista and has provided a platform for long-term value creation for our customers, employees, and shareholders. We share this announcement to ensure a smooth and orderly succession process as we identify the best possible leader for the future.”
Tags:
Mon. 29 April 2024
12:30 pm EST (New York)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
1:00 pm EST (New York)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Fri. 3 May 2024
1:00 pm EST (New York)
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
Tue. 7 May 2024
8:00 pm EST (New York)
You got this! Diagnosis and management of common oral lesions
Thu. 9 May 2024
8:00 pm EST (New York)
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
Mon. 13 May 2024
9:00 am EST (New York)
CREATING MORE PRACTICE TIME THROUGH EFFICIENCY: IMPROVED ACCURACY AND DELEGATION
Mon. 13 May 2024
1:00 pm EST (New York)
To post a reply please login or register